Clinical trial · Observational
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
NCT06161051CI-TRIAL-00072056completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- Capmatinib
- label
- IO monotherapy
- label
- Chemotherapy alone
- label
- IO + chemotherapy
Primary outcomes (6)
- measure
- Time-to-treatment discontinuation (TTD)
- timeFrame
- Up to approximately 5 years
- measure
- Real-world overall response rate (rwORR)
- timeFrame
- Up to approximately 5 years
- description
- Proportion of patients with best overall response of either a complete response (CR) or partial response (PR) to the line of therapy based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or per healthcare professional (HCP) assessment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient was aged ≥ 18 years at the time of NSCLC diagnosis. * Had histologically confirmed advanced (stage IIIB, IIIC, or IV) NSCLC with MET exon 14 skipping mutation. * Initiated first-line (1L) treatment for aNSCLC between 1 January 2017 and date of data abstraction with one of the following treatment regimen: * Capmatinib * IO agent in monotherapy (e.g., atezolizumab, pembrolizumab) * CT regimen, single agent or combinations of CT agents (e.g., platinum agents, taxane agents, gemcitabine, pemetrexed) * Combination regimen containing IO and CT agents * Had ≥ 6 months of potential follow-up time after the initiation of 1L treatment for aNSCLC, except if the patient died sooner. * Living or deceased at the time of chart abstraction. Exclusion Criteria: * Presence of other mutations (e.g., EGFR, ALK, ROS1, RET, NTRK, BRAF, or KRAS) at any time. * Treatment with other MET inhibitors such as crizotinib or tepotinib at any time during the study period. * Participation in clinical trials related to treatment for NSCLC at any timepoint.
References
Publications (0)
Data not yet available
No reference posted for this study.